LungLife AI: Edison Open House Healthcare 2022

LungLife AI: Edison Open House Healthcare 2022

LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.

• Please explain the importance of the early detection of lung cancer.
• What are the current issues with screening?
• How does LungLife help to overcome these problems?
• How does artificial intelligence (AI) help?
• How will people be prompted to get a test earlier, if symptoms only occur later in the disease?
• Following the recent announcement of your US PLA code, how is this significant to your commercialisation?
• Can your lung cancer product be adapted for other cancers?
• Tell us about the White Ribbon Project and its aim to reduce the stigma around lung cancer.
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.